Add BrightSurf on Google Email

Scientists move closer to treatment for Huntington's disease

Researchers have developed a safer and more specific CRISPR/Cas9 system to treat Huntington's disease, a neurodegenerative disorder caused by a defective gene. The new technique successfully inactivates the mutant gene and reduces toxic protein synthesis, offering hope for a potential cure.

SourceFrontiers·JournalFrontiers in Neuroscience·DateFeb 26, 2018

Letting silenced genes speak

Researchers at UConn Health have reversed Prader-Willi syndrome in lab-grown brain cells by targeting the ZNF274 protein, which silences many genes. The breakthrough provides clues for treating this genetic disorder and offers new hope for patients with life-threatening childhood obesity.

SourceUniversity of Connecticut·JournalHuman Molecular Genetics·DateJan 25, 2018

Study examines link between epilepsy and mood disorders

A new study suggests a shared genetic susceptibility between epilepsy and mood disorders, particularly in individuals with focal epilepsy. The study found a significant increase in lifetime prevalence of mood disorders among people with focal epilepsy compared to those with generalized epilepsy.

SourceWiley·JournalEpilepsia·DateJan 11, 2018

First discover the disorder and then find the patients

Scientists at Bielefeld University confirm the presence of a previously unknown genetic defect 'MPS III-E' causing progressive blindness and inner ear hearing impairment in patients. Biochemical studies revealed that the disorder is caused by an enzyme deficiency, which can be treated with biotechnological enzyme replacement therapy.

SourceBielefeld University·JournalGenetics in Medicine·DateJan 5, 2018

Creating brain cells to detect Tourette's

Researchers at Rutgers University created brain cells from blood samples of individuals in a three-generation family with Tourette syndrome. The study found that a mutation in the PNKD gene is likely the cause of the disorder, which affects one in every 100-150 people in the US.

SourceRutgers University·JournalMolecular Psychiatry·DateSep 25, 2017

Spark Therapeutics announces publication in The Lancet of pivotal Phase 3 clinical trial data for investigational voretigene neparvovec

The Phase 3 clinical trial data showed statistically significant and clinically meaningful improvements in functional vision and visual field in participants with RPE65-mediated inherited retinal disease. Participants demonstrated marked gains in full-field light sensitivity and peripheral vision.

SourceTen Bridge Communications·JournalThe Lancet·DateJul 14, 2017

Hoarding symptoms moderately stable during adolescence

A study found that hoarding symptoms are heritable and moderately stable between 15-18 years old, suggesting genetic effects play a significant role. The findings could help inform treatments development for young people experiencing hoarding symptoms, preventing potential progression into Hoarding Disorder as adults.

SourcePLOS·JournalPLOS ONE·DateJun 28, 2017

What percentage of ALS is genetic?

A study published in Neurology found that approximately 17% of ALS cases are caused by gene mutations, with rare and likely harmful variants being more common in those with the disease. The research highlights the importance of genetic factors in ALS development and suggests a larger percentage of sporadic cases may be linked to genetics.

SourceAmerican Academy of Neurology·JournalNeurology·DateJun 21, 2017